Darrell,
you wear me out constantly having to correct you. Cisplatin is typically administered at three week intervals beginning with the first day of radiation. It is still considered "front line" standard of care, in conjunction with, and as an adjunct to radiation therapy. This is the pharmacuetical manufacturer's recommendation for greatest efficacy. On rare occasions they will modify the infusion rates for patients with compromised livers or kidneys and give smaller doses at more frequent intervals. Cisplatin is very toxic. Cisplatin has actually been in use for quite a while and is very effective when used with radiation. Carboplatin is an alternative and not quite as effective but won't cause deafness and the nephrotoxicity issues aren't as severe. Some studies have suggested as much as 13% higher survival rate with the Cisplatin/Radiation combination, so I wouldn't be kicking myself too hard about not choosing something else.

Erbitux, taxotere, F5U, etc., are not "front line", but "second line" treatments and the doctors will fiddle with the infusion intervals with them since they are more in the experimental category. To date ct, by itself, has not shown to be a front line method of treatment.

I have noticed a trend to offer Erbitux, post rad, but I would speculate that they gathering data for efficacy studies. It just got cleared by the FDA for H&N application.

All of this stuff I mention is related to primary care - not for treatment of
metastatic disease. There are "no hold's barred" for recurrence or metastatic treatments. Taxol, for instance, is typically indicated and administered for breast cancer.